Price alert —
Sign in to get a one-time email the moment ARTL crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · ARTL
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare ARTL vs peers
Line ARTL up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with ARTL
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-02-24 | -0.12 | -4.71 | +97.5% | -6.9% |
| 2025-11-12 | -11.91 | -2.46 | -384.1% | +0.0% |
| 2025-08-13 | -16.83 | -12.57 | -33.9% | -0.4% |
| 2025-05-13 | -12.96 | -2.34 | -453.9% | -3.4% |
| 2025-03-03 | -21.06 | -6.84 | -207.9% | +3.5% |
| 2024-11-12 | -6.30 | -32.04 | +80.3% | -6.0% |
| 2024-08-13 | -13.50 | -15.24 | +11.4% | +1.5% |
| 2024-05-13 | -14.04 | -18.99 | +26.1% | +2.4% |
| 2024-03-25 | -17.82 | -10.02 | -77.8% | -4.4% |
| 2023-11-13 | -14.94 | -11.64 | -28.4% | +3.1% |
| 2023-08-10 | -10.08 | -14.67 | +31.3% | -2.8% |
| 2023-05-11 | -13.68 | -19.56 | +30.1% | -1.2% |
| 2023-03-31 | -21.24 | -13.14 | -61.6% | +7.2% |
| 2022-11-08 | -14.76 | -16.44 | +10.2% | -7.7% |
| 2022-08-09 | -16.20 | -15.30 | -5.9% | -1.2% |
| 2021-11-29 | -18.90 | -26.10 | +27.6% | -4.8% |
| 2021-07-12 | -27.00 | -21.60 | -25.0% | — |
| 2021-04-13 | -29.70 | -31.05 | +4.3% | — |
| 2021-01-14 | -37.80 | -27.00 | -40.0% | — |
| 2020-11-04 | -54.00 | -97.20 | +44.4% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ARTL ★ | $0B | — | -1.3 | — | — | 0.2 | — | — | — | -76.90% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 1.34%
| Holder | Shares | % out |
|---|---|---|
| Kathmere Capital Management, Llc | 13,250 | 0.38% |
| Jane Street Group, LLC | 13,079 | 0.38% |
| Vanguard Capital Management LLC | 10,129 | 0.29% |
| Vanguard Fiduciary Trust Co | 3,139 | 0.09% |
| Citigroup Inc. | 3,076 | 0.09% |
| Tower Research Capital LLC (TRC) | 2,826 | 0.08% |
| Altshuler Shaham Ltd | 889 | 0.03% |
| Rothschild Investment LLC | 2 | — |
| Clear Street Group Inc. | 100 | — |
| Osaic Holdings Inc. | 1 | — |
Insider activity · 90d
No insider trades for ARTL in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-17 | FORM 8-K | view · |
| DEF 14A | 2026-06-05 | DEF 14A | view · |
| 8-K | 2026-05-27 | FORM 8-K | view · |
| 8-K | 2026-05-15 | FORM 8-K | view · |
| 10-Q | 2026-05-14 | FORM 10-Q | view · |
| S-1 | 2026-04-07 | FORM S-1 | view · |
| 8-K | 2026-04-07 | FORM 8-K | view · |
| 8-K | 2026-03-30 | FORM 8-K | view · |
| 8-K | 2026-03-26 | FORM 8-K | view · |
| S-1 | 2026-03-24 | FORM S-1 | view · |
| S-1 | 2026-03-20 | FROM-S-1 | view · |
| 8-K | 2026-03-18 | FORM 8-K | view · |
| 8-K | 2026-03-17 | FORM 8-K | view · |
| 8-K | 2026-03-06 | FORM 8-K | view · |
| 10-K | 2026-02-24 | FORM 10-K | view · |
| 8-K | 2026-02-05 | FORM 8-K | view · |
| 8-K | 2026-02-05 | FORM 8-K | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 4 | 2026-02-02 | FORM 4 | view · |
| 8-K | 2026-01-30 | FORM 8-K | view · |
| 8-K | 2026-01-16 | FORM 8-K | view · |
| 8-K | 2026-01-02 | FORM 8-K | view · |
| DEF 14A | 2025-12-11 | DEF 14A | view · |
| 8-K | 2025-11-25 | FORM 8-K | view · |
| S-1 | 2025-11-17 | FORM S-1 | view · |
| 8-K | 2025-11-14 | FORM 8-K | view · |
| 10-Q | 2025-11-12 | FORM 10-Q | view · |
| 8-K | 2025-10-31 | FORM 8-K | view · |
| 4 | 2025-10-30 | FORM 4 | view · |
| 4 | 2025-10-30 | FORM 4 | view · |
| 4 | 2025-10-30 | FORM 4 | view · |
| 8-K | 2025-10-27 | FORM 8-K | view · |
| 8-K | 2025-10-17 | FORM 8-K | view · |
| 8-K | 2025-10-01 | FORM 8-K | view · |
| 8-K | 2025-09-15 | FORM 8-K | view · |
| 8-K | 2025-09-10 | FORM 8-K | view · |
| 8-K | 2025-09-05 | FORM 8-K | view · |
| 8-K | 2025-09-03 | FORM 8-K | view · |
| 8-K | 2025-08-29 | FORM 8-K | view · |
| 8-K | 2025-08-20 | FORM 8-K | view · |
| 10-Q | 2025-08-13 | FORM 10-Q | view · |
| DEF 14A | 2025-08-07 | DEF 14A | view · |
| 8-K | 2025-08-07 | FORM 8-K | view · |
| 8-K | 2025-08-04 | FORM 8-K | view · |
| 8-K | 2025-07-18 | FORM 8-K | view · |
| S-1 | 2025-07-11 | FORM S-1 | view · |
| 8-K | 2025-07-11 | FORM 8K | view · |
| 4 | 2025-07-07 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-06-26 | FORM 8-K | view · |
| 8-K | 2025-06-13 | FORM 8-K | view · |
| 8-K | 2025-05-23 | FORM 8-K | view · |
| 10-Q | 2025-05-13 | FORM 10-Q | view · |
| 4 | 2025-05-05 | FORM 4 | view · |
| 4 | 2025-05-05 | FORM 4 | view · |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Options picks · ARTL
ITM + OTM ideas from the latest scanLoading…
Congress trades · ARTL
STOCK Act disclosuresLoading…
SEC filings & insiders · ARTL
EDGAR · liveLoading…
Holders · ARTL
Institutions & insider activityLoading…